20:29 , Jul 31, 2019 |  BC Extra  |  Financial News

Alizé seeks to build out company with largest European A round this year

French biotech Alizé Pharma 3 is taking a more ambitious approach than its predecessors, and now has a €67 million ($74.5 million) series A round to fund two endocrine programs through Phase II testing and...
22:53 , Jul 23, 2019 |  BC Extra  |  Clinical News

July 23 Clinical Quick Takes: Achillion plans U.S. IND; plus Chiasma, Myovant, Marinus and Merck

Achillion plans U.S. IND after latest readout for ACH-5228  Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) rose $1.19 (50%) to $3.57 since announcing early Monday that multiple ascending doses of its CFD inhibitor ACH-5228 led to 95% complement...
17:00 , Aug 9, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A biomanufacturing method could enable ex vivo production of human platelets to treat thrombocytopenia and other hematologic indications. In human induced pluripotent stem (iPS) cell-derived megakaryocyte cell lines cultured in shaking flasks,...
21:38 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Small cell lung cancer Patient sample and cell culture studies suggest promoting IGFBP5 expression or inhibiting POU2F3 or IGF1R could help treat POU2F3-expressing small cell lung cancer (SCLC). In tumor samples from SCLC patients,...
22:15 , Jun 27, 2018 |  BC Extra  |  Preclinical News

New small cell lung cancer subtype identified

In a Genes & Development paper , scientists at Cold Spring Harbor Laboratory identified a new subtype of small cell lung cancer defined by high levels of POU class 2 homeobox 3 (POU2F3; OCT11) and...
17:02 , Feb 6, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample and mouse studies suggest promoting IGFBP3 expression could help treat MYCN-driven neuroblastoma. In five MYCN-driven neuroblastoma cell lines, IGFBP3 encoded by a plasmid vector decreased viability compared with GFP. In...
16:53 , Aug 18, 2017 |  BioCentury  |  Emerging Company Profile

Teasing out Th1

EpiThany Inc. aims to increase the potency of therapeutic cancer vaccines by designing antigens that selectively activate immune-stimulating Th1 cells, without incurring the immunosuppressive effects caused by Th2 cell activation. Like most cancer vaccines in...
20:15 , May 25, 2017 |  BC Innovations  |  Finance

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...
23:59 , Jan 10, 2017 |  BC Extra  |  Financial News

Labcorp buys into Sera, to distribute preterm birth test

Sera Prognostics Inc. (Salt Lake City, Utah) raised $40 million in a series C round led by Laboratory Corp. of America Holdings (NYSE:LH). Also participating were existing investors Domain Associates, InterWest Partners , Catalyst Health...
07:00 , Aug 1, 2016 |  BioCentury  |  Product Development

IGF synergy in cancer

Despite a history of failures in targeting the insulin-like growth factor receptor for cancer, Boehringer Ingelheim GmbH and Eli Lilly and Co. have several hypotheses that support greater cell cycle arrest and the potential to...